

Raccolta informazioni su Gruppi di Ricerca- DiSCOG

CAPOGRUPPO

Nominativo	Giacomo Novara
Ruolo Universitario	Ricercatore confermato
SSD	Med/24
Ruolo ospedaliero (se presente)	Dirigente di I livello
Sezione di appartenenza	Clinica Urologica
Unità Operativa Semplice (se presente)	Urologia
Unità Operativa Complessa	

LINEE DI RICERCA (solo linee di ricerca attuali; se presenti piu' linee di ricerca indicarle con un numero e fare riferimento al numero per tutte le informazioni sottostanti, quando appropriato)

- 1) Studio dei fattori prognostici delle neoplasie uroteliali vescicali e dell'alta via
- 2) Studio dei fattori prognostici delle neoplasie renali parenchimali
- 3)

AFFERENTI AL GRUPPO DI RICERCA

1) PERSONALE UNIVERSITARIO (PROFESSORI E RICERCATORI)

Nominativo	Ruolo (SSD)	Dipartimento di afferenza
Filiberto Zattoni	Professore ordinario	DISCOG
Vincenzo Ficarra	Professore associato	DISCOG

2) PERSONALE NON STRUTTURATO (DOTTORANDI, SPECIALIZZANDI, ASSEGNISTI, BORSISTI)

Nominativo	Ruolo ** per gli specializzandi e dottorandi specificare la scuola di appartenenza	Dipartimento di afferenza
-	-	-
-	-	-
-	-	-
-	-	-

3) PERSONALE TECNICO DI LABORATORIO STRUTTURATO

Nominativo	Livello	Dipartimento di afferenza
-	-	-
-	-	-
-	-	-
-	-	-

4) PERSONALE DI RICERCA APPARTENENTE AD ALTRE AMMINISTRAZIONI (IOV, AZIENDA OSPEDALIERA, VIMM, ETC)

Nominativo	Ruolo	Ente di appartenenza
-	-	-
-	-	-
-	-	-
-	-	-

COLLABORAZIONI NAZIONALI E INTERNAZIONALI SOSTENUTI DA: PROGETTI DI RICERCA/PUBBLICAZIONI/SCAMBI DI PERSONALE (ultimi 5 anni, sostanziate da piu' pubblicazioni e/o progetti di ricerca in comune)

Collaborazioni scientifiche sono in corso con le seguenti università americane: 1) Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY; 2) John Hopkins University, Baltimore, MD; 3) Baylor College of Medicine, Houston, TX; 4) University of Southern California, Los Angeles, California; 5) University of Texas, M. D. Anderson Cancer Center, Houston, TX; 6) University of Michigan, Ann Arbor, MI; 7) University of Texas Southwestern Medical Center, Dallas, TX; 8) Penn State Milton S. Hershey Medical Center, Hershey, PA; 9) McGill University, Montreal, QC, Canada; 10) University of Montreal, Canada; 11) Laval University, Québec City, Québec, Canada.

Collaborazioni scientifiche sono in corso con le seguenti istituzioni europee: 1) University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2) Cochin Hospital, APHP, Paris 5 University, Paris, France; 3) Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; 4) Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autónoma de Madrid, Madrid, Spain; 5) Ludwig-Maximilians-Universität München, Klinikum Grosshadern, Munich, Germany; 6) University of Ulm, Ulm, Germany; 7) University of Graz, Austria; 8) Università Vita e Salute San Raffaele di Milano.

PARTECIPAZIONE A PROGETTI INTERNAZIONALI (ultimi 5 anni; indicare per ogni linea di ricerca)

--

FINANZIAMENTI (ultimi 5 anni; indicare per ogni linea di ricerca)

Lavori prodotti in merito alla linea di ricerca "Studio dei fattori prognostici delle neoplasie uroteliali vescicali e dell'alta via"

1. RICERCA SCIENTIFICA FONDI QUOTA EX 60% - BANDO 2009 CODICE: 60A07-3980/09 TITOLO: "VALUTAZIONE DEI FATTORI PROGNOSTICI CLINICI, PATOLOGICI E MOLECOLARI DEL CARCINOMA TRANSIZIONALE DELLA VESCICA E DELL'ALTRA VIA ESCRETRICE" (IL PROGETTO È STATO FINANZIATO PER € 5778)
2. RICERCA SCIENTIFICA FONDI QUOTA EX 60% - BANDO 2010 CODICE: 60A07-5053/10 TITOLO: "VALUTAZIONE DEI FATTORI PROGNOSTICI CLINICI E PATOLOGICI NEI PAZIENTI CON CARCINOMA UROTELIALE DELLA VESCICA SOTTOPOSTI A CISTECTOMIA RADICALE" (IL PROGETTO È STATO FINANZIATO PER €3952)
3. RICERCA SCIENTIFICA FONDI QUOTA EX 60% - BANDO 2011 CODICE: 60A07-7914/11 TITOLO: "FATTORI PROGNOSTICI DEL CARCINOMA TRANSIZIONALE VESCICALE E DELL'ALTA VIA ESCRETRICE" (IL PROGETTO È STATO FINANZIATO PER €3579)

PUBBLICAZIONI (ultimi 5 anni; solo pubblicazioni ISI e non abstract; indicare per ogni linea di ricerca)

Lavori prodotti in merito alla linea di ricerca "Studio dei fattori prognostici delle neoplasie uroteliali vescicali e dell'alta via"

1: Xylinas E, Kluth L, Passonni N, Trinh QD, Rieken M, Lee RK, Fajkovic H, Novara G, Margulis V, Raman JD, Lotan Y, Rouprêt M, Aziz A, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Walton T, Karakiewicz PI, Montorsi F, Zerbib M, Scherr DS, Shariat SF; for the

UTUC Collaboration. Prediction of Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool. *Eur Urol*. 2013 Sep 19. doi:pii: S0302-2838(13)00990-1. 10.1016/j.eururo.2013.09.003. [Epub ahead of print] PubMed PMID: 24070577.

2: Kluth LA, Xylinas E, Kent M, Hagiwara M, Kikuchi E, Matsumoto K, Ikeda M, Dalpiaz O, Zigeuner R, Aziz A, Fritsche HM, Deliere A, Raman JD, Bensalah K, Al-Matar B, Gakis G, Novara G, Klatte T, Remzi M, Comploj E, Pycha A, Rouprêt M, Tagawa ST, Chun FK, Scherr DS, Vickers A, Shariat SF. PREDICTORS OF SURVIVAL IN PATIENTS WITH DISEASE RECURRENCE FOLLOWING RADICAL NEPHROURETERECTOMY. *BJU Int*. 2013 Jul 19. doi: 10.1111/bju.12369. [Epub ahead of print] PubMed PMID: 24053651.

3: Xylinas E, Rink M, Margulis V, Clozel T, Lee RK, Comploj E, Novara G, Raman JD, Lotan Y, Weizer A, Roupret M, Pycha A, Scherr DS, Seitz C, Ficarra V, Trinh QD, Karakiewicz PI, Montorsi F, Zerbib M, Shariat SF; UTUC Collaboration. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. *BJU Int*. 2013 Aug;112(4):453-61. doi: 10.1111/j.1464-410X.2012.11649.x. Epub 2013 Mar 6. PubMed PMID: 23464979.

4: Xylinas E, Rink M, Margulis V, Faison T, Comploj E, Novara G, Raman JD, Lotan Y, Guillonneau B, Weizer A, Pycha A, Scherr DS, Seitz C, Sun M, Trinh QD, Karakiewicz PI, Montorsi F, Zerbib M, Gönen M, Shariat SF; UTUC Collaboration. Prediction of true nodal status in patients with pathological lymph node negative upper tract urothelial carcinoma at radical nephroureterectomy. *J Urol*. 2013 Feb;189(2):468-73. doi: 10.1016/j.juro.2012.09.036. Epub 2012 Dec 14. PubMed PMID: 23253960.

5: Rink M, Zabor EC, Furberg H, Xylinas E, Ehdai B, Novara G, Babjuk M, Pycha A, Lotan Y, Trinh QD, Chun FK, Lee RK, Karakiewicz PI, Fisch M, Robinson BD, Scherr DS, Shariat SF. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. *Eur Urol*. 2013 Sep;64(3):456-64. doi: 10.1016/j.eururo.2012.11.039. Epub 2012 Nov 27. PubMed PMID: 23206854.

6: Xylinas E, Cha EK, Sun M, Rink M, Trinh QD, Novara G, Green DA, Pycha A, Fradet Y, Daneshmand S, Svatek RS, Fritsche HM, Kassouf W, Scherr DS, Faison T, Crivelli JJ, Tagawa ST, Zerbib M, Karakiewicz PI, Shariat SF. Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. *Br J Cancer*. 2012 Nov 20;107(11):1826-32. doi: 10.1038/bjc.2012.464. PubMed PMID: 23169335; PubMed Central PMCID: PMC3504939.

7: Rouprêt M, Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR, Fajkovic H, Lotan Y, Raman JD, Zigeuner R, Remzi M, Bolenz C, Novara G, Kassouf W, Ouzzane A, Rozet F, Cussenot O, Martinez-Salamanca JI, Fritsche HM, Walton TJ, Wood CG, Bensalah K, Karakiewicz PI, Montorsi F, Margulis V, Shariat SF; French National Database on Upper Tract Tumors; Upper Tract Urothelial Carcinoma Collaboration. Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. *J Urol*. 2013 May;189(5):1662-9. doi: 10.1016/j.juro.2012.10.057. Epub 2012 Oct 24. PubMed PMID: 23103802.

8: Xylinas E, Rink M, Novara G, Green DA, Clozel T, Fritsche HM, Guillonneau B, Lotan Y, Kassouf W, Tilki D, Babjuk M, Karakiewicz PI, Montorsi F, Abdennabi J, Trinh QD, Svatek RS, Scherr DS, Zerbib M, Shariat SF. Predictors of survival in patients with soft tissue surgical margin involvement at radical cystectomy. *Ann Surg Oncol*. 2013 Mar;20(3):1027-34. doi: 10.1245/s10434-012-2708-5. Epub 2012 Oct 26. PubMed PMID: 23099729.

9: Fajkovic H, Cha EK, Xylinas E, Rink M, Pycha A, Seitz C, Bolenz C, Dunning A, Novara G, Trinh QD, Karakiewicz PI, Margulis V, Raman JD, Walton TJ, Baba S, Carballido J, Otto W, Montorsi F, Lotan Y, Kassouf W, Fritsche HM, Bensalah K, Zigeuner R, Scherr DS, Sonpavde G, Roupret M, Shariat SF. Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. *World J Urol*. 2013 Feb;31(1):5-11. doi: 10.1007/s00345-012-0939-5. Epub 2012 Sep 26. PubMed PMID: 23011256.

10: Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M, Brisuda A, Hansen J, Green DA, Aziz A, Cha EK, Novara G, Chun FK, Lotan Y, Bastian PJ, Tilki D, Gontero P, Pycha A, Baniel J, Mano R, Ficarra V, Trinh QD, Tagawa ST, Karakiewicz PI, Scherr DS, Sjoberg DD, Shariat SF; Bladder Cancer Research Consortium. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. *BJU Int*. 2013 Mar;111(3 Pt B):E30-6. doi:10.1111/j.1464-410X.2012.11433.x. Epub 2012 Sep 3. PubMed PMID: 22938654.

11: Rink M, Furberg H, Zabor EC, Xylinas E, Babjuk M, Pycha A, Lotan Y, Karakiewicz PI, Novara G, Robinson BD, Montorsi F, Chun FK, Scherr DS, Shariat SF. Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. *Eur Urol*. 2013 Apr;63(4):724-32. doi: 10.1016/j.eururo.2012.08.025. Epub 2012 Aug 21. PubMed PMID: 22925575.

12: Fajkovic H, Cha EK, Jeldres C, Robinson BD, Rink M, Xylinas E, Chromcecki TF, Breinl E, Svatek RS, Donner G, Tagawa ST, Tilki D, Bastian PJ, Karakiewicz PI, Volkmer BG, Novara G, Joul A, Faison T, Sonpavde G, Daneshmand S, Lotan Y, Scherr DS, Shariat SF. Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis. *Eur Urol*. 2012 Jul 20. doi:pii: S0302-2838(12)00831-7. 10.1016/j.eururo.2012.07.026. [Epub ahead of print] PubMed PMID: 22877503.

13: Rink M, Shariat SF, Xylinas E, Fitzgerald JP, Hansen J, Green DA, Kamat AM, Novara G, Daneshmand S, Fradet Y, Tagawa ST, Bastian PJ, Kassouf W, Trinh QD, Karakiewicz PI, Fritsche HM, Tilki D, Chun FK, Volkmer BG, Babjuk M, Merseburger AS, Scherr DS, Lotan Y, Svatek RS. Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy? *World J Urol*. 2012 Dec;30(6):807-14. doi: 10.1007/s00345-012-0910-5. Epub 2012 Jul 26. PubMed PMID: 22832587.

14: Rink M, Hansen J, Cha EK, Green DA, Babjuk M, Svatek RS, Xylinas E, Tagawa ST, Faison T, Novara G, Karakiewicz PI, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Comploj E, Tilki D, Bastian PJ, Chun FK, Dahlem R, Scherr DS, Shariat SF. Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. *BJU Int*. 2013 Jan;111(1):74-84. doi: 10.1111/j.1464-410X.2012.11356.x. Epub 2012 Jul 19. PubMed PMID: 22809039.

15: Rink M, Sjoberg D, Comploj E, Margulis V, Xylinas E, Lee RK, Hansen J, Cha EK, Raman JD, Remzi M, Bensalah K, Novara G, Matin SF, Chun FK, Kikuchi E, Kassouf W, Martinez-Salamanca JI, Lotan Y, Seitz C, Pycha A, Zigeuner R, Karakiewicz PI, Scherr DS, Vickers AJ, Shariat SF. Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. *Ann Surg Oncol*. 2012 Dec;19(13):4337-44. doi: 10.1245/s10434-012-2499-8. Epub 2012 Jul 18. PubMed PMID: 22805867; PubMed Central PMCID: PMC3576920.

16: Rink M, Xylinas E, Margulis V, Cha EK, Ehdai B, Raman JD, Chun FK, Matsumoto K, Lotan Y, Furberg H, Babjuk M, Pycha A, Wood CG,

Karakiewicz PI, Fisch M, Scherr DS, Shariat SF; Upper Tract Urothelial Carcinoma Collaboration. Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. *Eur Urol.* 2013 Jun;63(6):1082-90. doi: 10.1016/j.eururo.2012.06.029. Epub 2012 Jun 22. PubMed PMID: 22743166.

17: Shariat SF, Rink M, Ehdaie B, Xylinas E, Babjuk M, Merseburger AS, Svatek RS, Cha EK, Tagawa ST, Fajkovic H, Novara G, Karakiewicz PI, Trinh QD, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Chun FK, Sonpavde G, Joul A, Scherr DS, Gonen M. Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. *Eur Urol.* 2013 Feb;63(2):371-8. doi: 10.1016/j.eururo.2012.06.008. Epub 2012 Jun 16. PubMed PMID: 22727174.

18: Chromecki TF, Cha EK, Fajkovic H, Rink M, Ehdaie B, Svatek RS, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, Daneshmand S, Kassouf W, Durand M, Novara G, Fritsche HM, Burger M, Izawa JJ, Brisuda A, Babjuk M, Pummer K, Shariat SF. Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. *BJU Int.* 2013 Feb;111(2):249-55. doi:10.1111/j.1464-410X.2012.11322.x. Epub 2012 Jun 21. PubMed PMID: 22727036.

19: Xylinas E, Rink M, Cha EK, Clozel T, Lee RK, Fajkovic H, Compj E, Novara G, Margulis V, Raman JD, Lotan Y, Kassouf W, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Zigeuner R, Pycha A, Scherr DS, Seitz C, Walton T, Trinh QD, Karakiewicz PI, Matin S, Montorsi F, Zerbib M, Shariat SF; for the Upper Tract Urothelial Carcinoma Collaboration. Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. *Eur Urol.* 2012 May 4. doi:pii: S0302-2838(12)00528-3.10.1016/j.eururo.2012.04.052. [Epub ahead of print] PubMed PMID: 22579047.

20: Xylinas E, Rink M, Margulis V, Karakiewicz P, Novara G, Shariat SF; Upper Tract Urothelial Carcinoma Collaboration (UTUCC). Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. *Eur Urol.* 2012 May;61(5):1069-70. doi: 10.1016/j.eururo.2012.02.042. Epub 2012 Feb 25. PubMed PMID: 22402109.

21: Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, Lee RK, Novara G, Hansen J, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Fisch M, Scherr DS, Shariat SF; Bladder Cancer Research Consortium (BCRC); Upper Tract Urothelial Carcinoma Collaboration (UTUCC). Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. *Eur Urol.* 2012 Oct;62(4):677-84. Epub 2012 Feb 15. PubMed PMID:22349570.

22: Roscigno M, Cha EK, Rink M, Seitz C, Novara G, Chromecki TF, Fritsche HM, Matsumoto K, Walton TJ, Carballido J, Filippo Da Pozzo L, Bertini R, Ficarra V, Otto W, Karakiewicz PI, Pycha A, Fajkovic H, Naspro R, Scherr DS, Montorsi F, Shariat SF. International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis. *BJU Int.* 2012 Sep;110(5):674-81. doi: 10.1111/j.1464-410X.2012.10930.x. Epub 2012 Feb 20. PubMed PMID: 22348322.

23: Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, Lotan Y, Raman JD, Kassouf W, Zigeuner R, Remzi M, Bensalah K, Weizer A, Kikuchi E, Bolenz C, Roscigno M, Koppie TM, Ng CK, Fritsche HM, Matsumoto K, Walton TJ, Ehdaie B, Tritschler S, Fajkovic H, Martínez-Salamanca JI, Pycha A, Langner C, Ficarra V, Patard JJ, Montorsi F, Wood CG, Karakiewicz PI, Margulis V. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *Eur Urol.* 2012 Apr;61(4):818-25. doi: 10.1016/j.eururo.2012.01.021. Epub 2012 Jan 23. PubMed PMID: 22284969.

24: Fajkovic H, Cha EK, Jeldres C, Donner G, Chromecki TF, Margulis V, Novara G, Lotan Y, Raman JD, Kassouf W, Seitz C, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Breinl E, Pycha A, Ficarra V, Montorsi F, Karakiewicz PI, Scherr DS, Shariat SF. Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. *J Urol.* 2012 Mar;187(3):845-51. doi: 10.1016/j.juro.2011.10.158. Epub 2012 Jan 15. PubMed PMID: 22248522.

25: Yafi FA, Novara G, Shariat SF, Gupta A, Matsumoto K, Walton TJ, Fritsche HM, El-Hakim A, Trischler S, Martínez-Salamanca JI, Seitz C, Ficarra V, Zattoni F, Karakiewicz PI, Kassouf W. Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. *BJU Int.* 2012 Jul;110(2 Pt 2):E7-13. doi: 10.1111/j.1464-410X.2011.10792.x. Epub 2011 Dec 16. PubMed PMID: 22177329.

26: Shariat SF, Ehdaie B, Rink M, Cha EK, Svatek RS, Chromecki TF, Fajkovic H, Novara G, David SG, Daneshmand S, Fradet Y, Lotan Y, Sagalowsky AI, Clozel T, Bastian PJ, Kassouf W, Fritsche HM, Burger M, Izawa JJ, Tilki D, Abdollah F, Chun FK, Sonpavde G, Karakiewicz PI, Scherr DS, Gonen M. Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. *Eur Urol.* 2012 Feb;61(2):237-42. doi: 10.1016/j.eururo.2011.10.011. Epub 2011 Oct 21. PubMed PMID: 22033174.

27: Chromecki TF, Mauermann J, Cha EK, Svatek RS, Fajkovic H, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Novara G, Fritsche HM, Ficarra V, Stief CG, Dinney CP, Skinner E, Pummer K, Fradet Y, Shariat SF. Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. *World J Urol.* 2012 Dec;30(6):753-9. doi: 10.1007/s00345-011-0772-2. Epub 2011 Oct 19. PubMed PMID: 22009117.

28: Chromecki TF, Cha EK, Fajkovic H, Margulis V, Novara G, Scherr DS, Lotan Y, Raman JD, Kassouf W, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Walton TJ, Pycha A, Ficarra V, Karakiewicz PI, Zigeuner R, Pummer K, Shariat SF. The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. *Eur Urol.* 2012 Feb;61(2):245-53. doi: 10.1016/j.eururo.2011.09.017. Epub 2011 Sep 28. PubMed PMID: 21975249.

29: Martinez-Salamanca JI, Shariat SF, Rodriguez JC, Chromecki TF, Ficarra V, Fritsche HM, Kassouf W, Matsumoto K, Cabello LO, Seitz C, Tritschler S, Walton TJ, Zattoni F, Novara G. Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study. *BJU Int.* 2012 Apr;109(8):1155-61. doi: 10.1111/j.1464-410X.2011.10479.x. Epub 2011 Aug 24. PubMed PMID: 21883847.

30: Chromecki TF, Bensalah K, Remzi M, Verhoest G, Cha EK, Scherr DS, Novara G, Karakiewicz PI, Shariat SF. Prognostic factors for upper urinary tract urothelial carcinoma. *Nat Rev Urol.* 2011 Jul 5;8(8):440-7. doi: 10.1038/nrurol.2011.96. Review. PubMed PMID: 21727942.

- 31: Nuhn P, Bastian PJ, Novara G, Svatek RS, Karakiewicz PI, Skinner E, Fradet Y, Izawa JI, Kassouf W, Montorsi F, Müller SC, Fritsche HM, Sonpavde G, Tilki D, Isbarn H, Ficarra V, Dinney CP, Shariat SF. Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. *Urol Int.* 2011;87(1):42-8. doi: 10.1159/000325463. Epub 2011 Jun 9. PubMed PMID:21659717.
- 32: Burger M, Shariat SF, Fritsche HM, Martinez-Salamanca JI, Matsumoto K, Chromecki TF, Ficarra V, Kassouf W, Seitz C, Pycha A, Tritschler S, Walton TJ, Novara G. No overt influence of lymphadenectomy on cancer-specific survival in organ-confined versus locally advanced upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy: a retrospective international, multi-institutional study. *World J Urol.* 2011 Aug;29(4):465-72. doi: 10.1007/s00345-011-0705-0. Epub 2011 Jun 1. PubMed PMID: 21630120.
- 33: Ehdaie B, Chromecki TF, Lee RK, Lotan Y, Margulis V, Karakiewicz PI, Novara G, Raman JD, Ng C, Lowrance WT, Scherr DS, Shariat SF. Obesity adversely impacts disease specific outcomes in patients with upper tract urothelial carcinoma. *J Urol.* 2011 Jul;186(1):66-72. doi: 10.1016/j.juro.2011.03.031. Epub 2011 May 14. PubMed PMID: 21571333.
- 34: Matsumoto K, Novara G, Gupta A, Margulis V, Walton TJ, Roscigno M, Ng C, Kikuchi E, Zigeuner R, Kassouf W, Fritsche HM, Ficarra V, Martignoni G, Tritschler S, Rodriguez JC, Seitz C, Weizer A, Remzi M, Raman JD, Bolenz C, Bensalah K, Koppie TM, Karakiewicz PI, Wood CG, Montorsi F, Iwamura M, Shariat SF. Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. *BJU Int.* 2011 Oct;108(8 Pt 2):E304-9. doi: 10.1111/j.1464-410X.2011.10188.x. Epub 2011 Apr 20. PubMed PMID:21507184.
- 35: Chromecki TF, Ehdaie B, Novara G, Pummer K, Zigeuner R, Seitz C, Pycha A, Lee RK, Cha EK, Karakiewicz PI, Ng C, Raman JD, Chun FK, Fritsche HM, Matsumoto K, Kassouf W, Walton TJ, Martínez-Salamanca JI, Scherr DS, Shariat SF. Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. *World J Urol.* 2011 Aug;29(4):473-80. doi: 10.1007/s00345-011-0677-0. Epub 2011 Apr 17. PubMed PMID: 21499902.
- 36: Kassouf W, Svatek RS, Shariat SF, Novara G, Lerner SP, Fradet Y, Bastian PJ, Aprikian A, Karakiewicz PI, Fritsche HM, Dinney CP, Tilki D, Kamat AM, Izawa JI, Ficarra V, Lotan Y, Sagalowsky AI, Schoenberg MP, Skinner EC. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. *Urol Oncol.* 2013 May;31(4):480-6. doi: 10.1016/j.urolonc.2011.02.011. Epub 2011 Apr 8. PubMed PMID: 21478035.
- 37: Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Scherr DS, Ficarra V, Dinney CP, Lotan Y, Fradet Y, Shariat SF. Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. *J Urol.* 2011 Apr;185(4):1216-21. doi: 10.1016/j.juro.2010.11.082. Epub 2011 Feb 22. PubMed PMID: 21334687.
- 38: Fedeli U, Novara G, Galassi C, Ficarra V, Schievano E, Gilardetti M, Muto G, Bertetto O, Ciccone G, Spolaore P. Population-based analyses of radical cystectomy and urinary diversion for bladder cancer in northern Italy. *BJU Int.* 2011 Oct;108(8 Pt 2):E266-71. doi: 10.1111/j.1464-410X.2011.10095.x. Epub 2011 Feb 14. PubMed PMID: 21320273.
- 39: Otto W, Shariat SF, Fritsche HM, Gupta A, Matsumoto K, Kassouf W, Martignoni G, Walton TJ, Tritschler S, Baba S, Bastian PJ, Martínez-Salamanca JI, Seitz C, Pycha A, Burger M, Karakiewicz PI, Ficarra V, Novara G. Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. *World J Urol.* 2011 Aug;29(4):487-94. doi: 10.1007/s00345-011-0645-8. Epub 2011 Jan 20. PubMed PMID: 21249372.
- 40: Svatek RS, Shariat SF, Novara G, Skinner EC, Fradet Y, Bastian PJ, Kamat AM, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Dinney CP. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. *BJU Int.* 2011 Mar;107(6):898-904. doi: 10.1111/j.1464-410X.2010.09628.x. Epub 2011 Jan 18. PubMed PMID: 21244604.
- 41: Sonpavde G, Khan MM, Lerner SP, Svatek RS, Novara G, Karakiewicz PI, Skinner E, Tilki D, Kassouf W, Fradet Y, Dinney CP, Fritsche HM, Izawa JI, Bastian PJ, Ficarra V, Schoenberg M, Sagalowsky AI, Lotan Y, Shariat SF. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. *J Urol.* 2011 Feb;185(2):456-61. doi: 10.1016/j.juro.2010.09.110. Epub 2010 Dec 17. PubMed PMID: 21167527.
- 42: Novara G, Ficarra V, Zattoni F. Is robot-assisted radical cystectomy the right way to reduce complications in patients undergoing radical cystectomy? *Eur Urol.* 2011 Feb;59(2):219-21. doi: 10.1016/j.eururo.2010.11.025. Epub 2010 Nov 26. PubMed PMID: 21144645.
- 43: Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Ficarra V, Dinney CP, Lotan Y, Fradet Y, Shariat SF. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. *BJU Int.* 2011 Sep;108(5):687-92. doi:10.1111/j.1464-410X.2010.09902.x. Epub 2010 Nov 19. PubMed PMID: 21087453.
- 44: Walton TJ, Novara G, Matsumoto K, Kassouf W, Fritsche HM, Artibani W, Bastian PJ, Martínez-Salamanca JI, Seitz C, Thomas SA, Ficarra V, Burger M, Tritschler S, Karakiewicz PI, Shariat SF. Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. *BJU Int.* 2011 Aug;108(3):406-12. doi: 10.1111/j.1464-410X.2010.09826.x. Epub 2010 Nov 15. PubMed PMID: 21078048.
- 45: Fritsche HM, Novara G, Burger M, Gupta A, Matsumoto K, Kassouf W, Sircar K, Zattoni F, Walton T, Tritschler S, Baba S, Bastian PJ, Martínez-Salamanca JI, Seitz C, Otto W, Wieland WF, Karakiewicz PI, Ficarra V, Hartmann A, Shariat SF. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. *Urol Oncol.* 2012 Sep;30(5):666-72. doi: 10.1016/j.urolonc.2010.07.010. Epub 2010 Oct 8. PubMed PMID: 20933445.
- 46: Shariat SF, Favaretto RL, Gupta A, Fritsche HM, Matsumoto K, Kassouf W, Walton TJ, Tritschler S, Baba S, Matsushita K, Bastian PJ, Martínez-Salamanca JI, Seitz C, Pycha A, Otto W, Karakiewicz PI, Ficarra V, Novara G. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. *World J Urol.* 2011 Aug;29(4):481-6. doi: 10.1007/s00345-010-0594-7. Epub 2010 Oct 1. PubMed PMID: 20886219.
- 47: Seitz C, Gupta A, Shariat SF, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Otto W, Tritschler S, Bastian PJ, Carballido J, Ficarra V,

Karakiewicz PI, Artibani W, Mazzoleni G, Novara G. Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: an international validation study. *J Urol*. 2010 Nov;184(5):1895-900. doi: 10.1016/j.juro.2010.06.106. Epub 2010 Sep 17. PubMed PMID: 20846680.

48: Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche HM, Müller SC, Izawa JJ, Ficarra V, Sagalowsky AI, Schoenberg MP, Siefker-Radtke AO, Millikan RE, Dinney CP. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. *Clin Cancer Res*. 2010 Sep 1;16(17):4461-7. doi: 10.1158/1078-0432.CCR-10-0457. Epub 2010 Jul 22. PubMed PMID: 20651056.

49: Tilki D, Svatek RS, Novara G, Seitz M, Godoy G, Karakiewicz PI, Kassouf W, Fradet Y, Fritsche HM, Sonpavde G, Izawa JJ, Ficarra V, Lerner SP, Schoenberg M, Stief CG, Dinney CP, Skinner E, Lotan Y, Sagalowsky AI, Reich O, Shariat SF. Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. *J Urol*. 2010 Sep;184(3):888-94. doi: 10.1016/j.juro.2010.04.081. Erratum in: *J Urol*. 2010 Nov;184(5):2218. PubMed PMID: 20643448.

50: Tilki D, Svatek RS, Karakiewicz PI, Novara G, Seitz M, Sonpavde G, Gupta A, Kassouf W, Fradet Y, Ficarra V, Skinner E, Lotan Y, Sagalowsky AI, Stief CG, Reich O, Shariat SF. pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. *J Urol*. 2010 Aug;184(2):470-4. doi: 10.1016/j.juro.2010.04.007. Epub 2010 Jun 17. PubMed PMID: 20620401.

51: Novara G, Ficarra V. Does routine second transurethral resection affect the long-term outcome of patients with T1 bladder cancer? Why a flawed randomized controlled trial cannot address the issue. *Eur Urol*. 2010 Aug;58(2):193-4. doi: 10.1016/j.eururo.2010.04.012. Epub 2010 Apr 21. PubMed PMID: 20418013.

52: Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y, Lotan Y, Isbarn H, Capitanio U, Bastian PJ, Kassouf W, Fritsche HM, Izawa JJ, Tilki D, Dinney CP, Lerner SP, Schoenberg M, Volkmer BG, Sagalowsky AI, Shariat SF. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. *J Urol*. 2010 Jun;183(6):2165-70. doi: 10.1016/j.juro.2010.02.021. PubMed PMID: 20399473.

53: Tilki D, Reich O, Svatek RS, Karakiewicz PI, Kassouf W, Novara G, Ficarra V, Chade DC, Fritsche HM, Gerwens N, Izawa JJ, Lerner SP, Schoenberg M, Stief CG, Skinner E, Lotan Y, Sagalowsky AI, Shariat SF. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. *J Urol*. 2010 May;183(5):1757-63. doi: 10.1016/j.juro.2010.01.025. Epub 2010 Mar 17. PubMed PMID: 20299059.

54: Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, Fritsche HM, Izawa JJ, Ficarra V, Lerner SP, Sagalowsky AI, Schoenberg MP, Kamat AM, Dinney CP, Lotan Y, Marberger MJ, Fradet Y. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. *BJU Int*. 2010 May;105(10):1402-12. doi: 10.1111/j.1464-410X.2010.09217.x. Epub 2010 Feb 2. PubMed PMID: 20132195.

55: Tilki D, Reich O, Karakiewicz PI, Novara G, Kassouf W, Ergün S, Fradet Y, Ficarra V, Sonpavde G, Stief CG, Skinner E, Svatek RS, Lotan Y, Sagalowsky AI, Shariat SF. Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. *Eur Urol*. 2010 Jul;58(1):112-7. doi: 10.1016/j.eururo.2010.01.015. Epub 2010 Jan 20. PubMed PMID: 20097469.

56: Novara G, Ficarra V, Minja A, De Marco V, Artibani W. Functional results following vesica ileale Padovana (VIP) neobladder: midterm follow-up analysis with validated questionnaires. *Eur Urol*. 2010 Jun;57(6):1045-51. doi: 10.1016/j.eururo.2010.01.007. Epub 2010 Jan 16. PubMed PMID: 20096993.

57: Novara G, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Bastian PJ, Martínez-Salamanca JJ, Seitz C, Lemberger RJ, Burger M, El-Hakim A, Baba S, Martignoni G, Gupta A, Karakiewicz PI, Ficarra V, Shariat SF. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. *Eur Urol*. 2010 Jun;57(6):1064-71. doi: 10.1016/j.eururo.2009.12.029. Epub 2010 Jan 6. PubMed PMID: 20071073.

58: Tilki D, Svatek RS, Karakiewicz PI, Isbarn H, Reich O, Kassouf W, Fradet Y, Novara G, Fritsche HM, Bastian PJ, Izawa JJ, Stief CG, Ficarra V, Lerner SP, Schoenberg M, Dinney CP, Skinner E, Lotan Y, Sagalowsky AI, Shariat SF. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. *J Urol*. 2010 Jan;183(1):87-93. doi: 10.1016/j.juro.2009.08.145. Epub . PubMed PMID: 19942232.

59: Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JJ, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, Lotan Y, Shariat SF. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. *Eur Urol*. 2010 Feb;57(2):300-9. doi: 10.1016/j.eururo.2009.09.024. Epub 2009 Sep 12. PubMed PMID: 19766384.

60: Novara G, De Marco V, Aragona M, Boscolo-Berto R, Cavalleri S, Artibani W, Ficarra V. Complications and mortality after radical cystectomy for bladder transitional cell cancer. *J Urol*. 2009 Sep;182(3):914-21. doi: 10.1016/j.juro.2009.05.032. Epub 2009 Jul 17. PubMed PMID: 19616246.

61: Novara G, Ficarra V. Robotic-assisted laparoscopic radical cystectomy: where do we stand? *Int J Clin Pract*. 2009 Feb;63(2):185-8. doi: 10.1111/j.1742-1241.2008.01948.x. PubMed PMID: 19196355.

62: Novara G, De Marco V, Dalpiaz O, Galfano A, Bouygues V, Gardiman M, Martignoni G, Patard JJ, Artibani W, Ficarra V. Independent predictors of contralateral metachronous upper urinary tract transitional cell carcinoma after nephroureterectomy: multi-institutional dataset from three European centers. *Int J Urol*. 2009 Feb;16(2):187-91. doi: 10.1111/j.1442-2042.2008.02201.x. Epub 2008 Nov 27. PubMed PMID: 19054165.

63: Novara G, De Marco V, Dalpiaz O, Gottardo F, Bouygues V, Galfano A, Martignoni G, Patard JJ, Artibani W, Ficarra V. Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract. *BJU Int*. 2008

Jun;101(11):1368-74. doi: 10.1111/j.1464-410X.2008.07438.x. Epub 2008 Jan 30. PubMed PMID: 18241252.

64: Novara G, De Marco V, Gottardo F, Dalpiaz O, Bouygues V, Galfano A, Martignoni G, Patard JJ, Artibani W, Ficarra V. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers. *Cancer*. 2007 Oct 15;110(8):1715-22. PubMed PMID: 17724728.

65: Novara G, Ficarra V, Alrabi N, Dalpiaz O, Martignoni G, Galfano A, Cavalleri S, Artibani W. Prognostic factors in a recent series of patients treated with radical cystectomy for bladder cancer. *Urol Int*. 2005;75(1):10-6. PubMed PMID: 16037701.

66: Ficarra V, Dalpiaz O, Alrabi N, Novara G, Galfano A, Artibani W. Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. *BJU Int*. 2005 Apr;95(6):786-90. PubMed PMID: 15794783.

Lavori prodotti in merito alla linea di ricerca "Studio dei fattori prognostici delle neoplasie renali parenchimali":

1: Brookman-May SD, May M, Shariat SF, Novara G, Zigeuner R, Cindolo L, De Cobelli O, De Nunzio C, Pahernik S, Wirth MP, Longo N, Simonato A, Serni S, Siracusano S, Volpe A, Morgia G, Bertini R, Dalpiaz O, Stief C, Ficarra V; Members of the CORONA-Project, the SATURN-Project, and the Young Academic Urologists Renal Cancer Group. Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma - results from a comprehensive multi-centre database (CORONA/SATURN-Project). *BJU Int*. 2013 May 23. doi: 10.1111/bju.12246. [Epub ahead of print] PubMed PMID: 23890378.

2: Ficarra V, Novara G, Volpe A, Mottrie A. Robot-assisted vs traditional laparoscopic partial nephrectomy: the time for meta-analysis has not yet arrived. *BJU Int*. 2013 Aug;112(4):E334-6. doi: 10.1111/bju.12089. PubMed PMID: 23879916.

3: Tilki D, Nguyen HG, Dall'era MA, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. *Eur Urol*. 2013 Jul 10. doi:pii: S0302-2838(13)00663-5. 10.1016/j.eururo.2013.06.048. [Epub ahead of print] PubMed PMID: 23871402.

4: Klinghoffer Z, Tarride JE, Novara G, Ficarra V, Kapoor A, Shayegan B, Braga LH. Cost-utility analysis of radical nephrectomy versus partial nephrectomy in the management of small renal masses: Adjusting for the burden of ensuing chronic kidney disease. *Can Urol Assoc J*. 2013 Mar-Apr;7(3-4):108-13. doi: 10.5489/cuaj.502. PubMed PMID: 23671525; PubMed Central PMCID: PMC3650775.

5: Borghesi M, Schiavina R, Gan M, Novara G, Mottrie A, Ficarra V. Expanding utilization of robotic partial nephrectomy for clinical T1b and complex T1a renal masses. *World J Urol*. 2013 Jun;31(3):499-504. doi: 10.1007/s00345-013-1095-2. Epub 2013 May 5. PubMed PMID: 23645411.

6: Ficarra V, Bhayani S, Porter J, Buffi N, Lee R, Cestari A, Novara G, Mottrie A. Robot-assisted partial nephrectomy for renal tumors larger than 4 cm: results of a multicenter, international series. *World J Urol*. 2012 Oct;30(5):665-70. doi: 10.1007/s00345-012-0943-9. Epub 2012 Sep 11. PubMed PMID: 22965742.

7: Gontero P, Sun M, Antonelli A, Bertini R, Carini M, Carmignani G, Longo N, Martorana G, Minervini A, Mirone V, Morgia G, Novara G, Oderda M, Simeone C, Simonato A, Siracusano S, Tizzani A, Volpe A, Karakiewicz P, Ficarra V; Members of the SATURN Project-LUNA Foundation. External validation of the preoperative Karakiewicz nomogram in a large multicentre series of patients with renal cell carcinoma. *World J Urol*. 2012 Jul 31. [Epub ahead of print] PubMed PMID: 22847452.

8: Brookman-May S, May M, Shariat SF, Xylinas E, Stief C, Zigeuner R, Chromecki T, Burger M, Wieland WF, Cindolo L, Schips L, De Cobelli O, Rocco B, De Nunzio C, Feciche B, Truss M, Gilfrich C, Pahernik S, Hohenfellner M, Zastrow S, Wirth MP, Novara G, Carini M, Minervini A, Simeone C, Antonelli A, Mirone V, Longo N, Simonato A, Carmignani G, Ficarra V; Members of the CORONA project and the SATURN project. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). *Eur Urol*. 2013 Sep;64(3):472-7. doi: 10.1016/j.eururo.2012.06.030. Epub 2012 Jun 22. PubMed PMID: 22748912.

9: Siracusano S, Novara G, Antonelli A, Artibani W, Bertini R, Carini M, Carmignani G, Ciciliato S, Cunico SC, Lampropoulou N, Longo N, Martorana G, Minervini A, Mirone V, Simeone C, Simonato A, Valotto C, Zattoni F, Ficarra V; members of the SATURN Project - LUNA Foundation. Prognostic role of tumour multifocality in renal cell carcinoma. *BJU Int*. 2012 Dec;110(11 Pt B):E443-8. doi: 10.1111/j.1464-410X.2012.11121.x. Epub 2012 Apr 13. PubMed PMID: 22502873.

10: Ficarra V, Novara G, Mottrie A. Kidney cancer: zero-ischemia partial nephrectomy--further evaluations are needed. *Nat Rev Urol*. 2011 Nov 15;8(12):654-5. doi: 10.1038/nrurol.2011.175. PubMed PMID: 22083244.

11: Volpe A, Novara G, Antonelli A, Bertini R, Billia M, Carmignani G, Cunico SC, Longo N, Martignoni G, Minervini A, Mirone V, Simonato A, Terrone C, Zattoni F, Ficarra V; Surveillance and Treatment Update on Renal Neoplasms (SATURN) Project; Leading Urological No-Profit Foundation for Advanced Research (LUNA) Foundation. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. *BJU Int*. 2012 Jul;110(1):76-83. doi: 10.1111/j.1464-410X.2011.10690.x. Epub 2011 Nov 1. PubMed PMID: 22044519.

12: Antonelli A, Ficarra V, Bertini R, Carini M, Carmignani G, Corti S, Longo N, Martorana G, Minervini A, Mirone V, Novara G, Serni S, Simeone C, Simonato A, Siracusano S, Volpe A, Zattoni F, Cunico SC; members of the SATURN Project - LUNA Foundation. Elective partial nephrectomy is equivalent to radical nephrectomy in patients with clinical T1 renal cell carcinoma: results of a retrospective, comparative, multi-institutional study. *BJU Int*. 2012 Apr;109(7):1013-8. doi: 10.1111/j.1464-410X.2011.10431.x. Epub 2011 Aug 24. PubMed PMID: 21883829.

- 13: Zucchi A, Novara G, Costantini E, Antonelli A, Carini M, Carmignani G, Cosciani Cunico S, Fontana D, Longo N, Martignoni G, Minervini A, Mirone V, Porena M, Roscigno M, Schiavina R, Simeone C, Simonato A, Siracusano S, Terrone C, Ficarra V. Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma. *BJU Int.* 2012 Apr;109(8):1140-6. doi: 10.1111/j.1464-410X.2011.10517.x. Epub 2011 Aug 22. PubMed PMID: 21871053.
- 14: Novara G, Ficarra V. Is laparoscopic cryoablation a less invasive and effective procedure to treat small renal masses? *Eur Urol.* 2011 Sep;60(3):444-5; discussion 446-7. doi: 10.1016/j.eururo.2011.05.059. Epub 2011 Jun 12. PubMed PMID: 21680082.
- 15: Minervini A, Ficarra V, Rocco F, Antonelli A, Bertini R, Carmignani G, Cosciani Cunico S, Fontana D, Longo N, Martorana G, Mirone V, Morgia G, Novara G, Roscigno M, Schiavina R, Serni S, Simeone C, Simonato A, Siracusano S, Volpe A, Zattoni F, Zucchi A, Carini M; SATURN Project-LUNA Foundation. Simple enucleation is equivalent to traditional partial nephrectomy for renal cell carcinoma: results of a nonrandomized, retrospective, comparative study. *J Urol.* 2011 May;185(5):1604-10. doi: 10.1016/j.juro.2010.12.048. Epub 2011 Mar 21. PubMed PMID: 21419454.
- 16: Mottrie A, Schatteman P, De Wil P, De Troyer B, Novara G, Ficarra V. Validation of the preoperative aspects and dimensions used for an anatomical (PADUA) score in a robot-assisted partial nephrectomy series. *World J Urol.* 2013 Aug;31(4):799-804. doi: 10.1007/s00345-010-0639-y. Epub 2011 Feb 1. PubMed PMID: 21286726.
- 17: Ficarra V, Brunelli M, Cheng L, Kirkali Z, Lopez-Beltran A, Martignoni G, Montironi R, Novara G, Van Poppel H. Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. *Eur Urol.* 2010 Nov;58(5):655-68. doi: 10.1016/j.eururo.2010.08.001. Epub 2010 Aug 10. Review. PubMed PMID: 20727666.
- 18: Novara G, Ficarra V, Antonelli A, Artibani W, Bertini R, Carini M, Cosciani Cunico S, Imbimbo C, Longo N, Martignoni G, Martorana G, Minervini A, Mirone V, Montorsi F, Schiavina R, Simeone C, Serni S, Simonato A, Siracusano S, Volpe A, Carmignani G; SATURN Project-LUNA Foundation. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? *Eur Urol.* 2010 Oct;58(4):588-95. doi: 10.1016/j.eururo.2010.07.006. Epub 2010 Jul 23. Erratum in: *Eur Urol.* 2011 Jan;59(1):182. Schiavina, Roberto [corrected to Schiavina, Riccardo]. PubMed PMID: 20674150.
- 19: Ficarra V, Novara G. Kidney cancer: neoadjuvant targeted therapies in renal cell carcinoma. *Nat Rev Urol.* 2010 Feb;7(2):63-4. doi: 10.1038/nrurol.2010.2. PubMed PMID: 20145660.
- 20: Fedeli U, Novara G, Alba N, Ficarra V, Artibani W, Spolaore P. Trends from 1999 to 2007 in the surgical treatments of kidney cancer in Europe: data from the Veneto Region, Italy. *BJU Int.* 2010 May;105(9):1255-9. doi: 10.1111/j.1464-410X.2009.08929.x. Epub 2009 Oct 10. PubMed PMID: 19818073.
- 21: Ficarra V, Secco S, Fracalanza S, Novara G, Gidaro S, Cindolo L, Schips L. Expanding indication for elective nephron-sparing surgery in renal cell carcinoma. *Arch Ital Urol Androl.* 2009 Jun;81(2):86-90. Review. PubMed PMID: 19760862.
- 22: Ficarra V, Novara G, Secco S, Macchi V, Porzionato A, De Caro R, Artibani W. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. *Eur Urol.* 2009 Nov;56(5):786-93. doi: 10.1016/j.eururo.2009.07.040. Epub 2009 Aug 4. PubMed PMID: 19665284.
- 23: Ficarra V, Novara G, Martignoni G. The use of simplified versions of the Fuhrman nuclear grading system in clinical practice requires the agreement of a multidisciplinary panel of experts. *Eur Urol.* 2009 Nov;56(5):782-4; discussion 784-5. doi: 10.1016/j.eururo.2009.07.024. Epub 2009 Jul 28. PubMed PMID: 19660853.
- 24: Novara G, Secco S, Botteri M, De Marco V, Artibani W, Ficarra V. Factors predicting health-related quality of life recovery in patients undergoing surgical treatment for renal tumors: prospective evaluation using the RAND SF-36 Health Survey. *Eur Urol.* 2010 Jan;57(1):112-20. doi: 10.1016/j.eururo.2009.04.023. Epub 2009 Apr 21. PubMed PMID: 19406562.

TECNOLOGIA, METODICHE, COMPETENZE DISPONIBILI PER POSSIBILI FUTURE COLLABORAZIONI

--